Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily throughout North America. Products As of December 31, 2014, the company’s product portfolio has grown to a total of 54 products in its Sagent U.S. segment and 62 products in its Omega segment, which can be classified into the following 3 product categories: anti-infective, oncology, and critical care. The company’s anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. Critical care products in the company’s Omega segment also include certain allergy and phlebology medications. Anti-Infective Products Cefepime: Cefepime is a fourth-generation cephalosporin, an antibiotic used to treat various infections, including infections of the urinary tract, skin, and skin structure, as well as moderate to severe pneumonia, complicated intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Cefepime is the generic equivalent of Elan Corporation, plc’s MAXIPIME. Levofloxacin: Levofloxacin is a fluoroquinolone antibacterial indicated in adults 18 years of age or older with infections caused by designated, susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection and pyelonephritis. Levofloxacin is the generic equivalent of Johnson & Johnson’s Levaquin. Oncology Products Leucovorin Calcium: Leucovorin Calcium is a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer. Leucovorin Calcium is also used to treat people who have accidentally received an overdose of methotrexate or similar medications. Zoledronic Acid: Zoledronic Acid is a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers, such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. Zoledronic Acid 4mg is the generic equivalent of Novartis’ Zometa, and Zoledronic Acid 5mg is the generic equivalent of Novartis’ Reclast. In 2013, the company launched zoledronic acid at market formation in a 4mg vial presentation, a 4mg per 100mL premix bag presentation, and a 5mg per 100mL premix bag presentation . Critical Care Products Heparin: Heparin is an anticoagulant used to prevent and treat blood clotting, especially during and after surgery and dialysis. The company offers nine different presentations of heparin sodium injection in latex-free vials, including 1,000 USP units per mL, 10,000 USP units per 10 mL, 30,000 USP units per 30 mL, 10,000 USP units per mL, 40,000 USP units per 4 mL, 5,000 USP units per mL, 50,000 USP units per 10 mL, 2,000 USP units per 2 mL and 20,000 USP units per mL. Propofol: Propofol is a sedative used to induce and maintain general anesthesia during surgical procedures. Propofol is the generic equivalent of Fresenius Kabi’s Diprivan. In 2013, the company launched Propofol through a supply and distribution agreement with Teva Pharmaceutical Industries Ltd. Sales and Marketing The company markets its products in both the U.S. and Canada to group purchasing organizations (GPOs), specialty distributors and a group of end-user customers. The five major U.S. GPOs include AmeriNet, Inc.; HealthTrust Purchasing Group; MedAssets Inc.; Novation, LLC; and Premier, Inc. Acquisitions In 2014, the company , through its wholly-owned subsidiary, Sagent Acquisition Corp., a Canadian company, acquired the capital stock of 7685947 Canada Inc., and its subsidiary, Omega Laboratories Limited (collectively, Omega), a privately held Canadian pharmaceutical and specialty healthcare products company. Customers The company distributes its products primarily through pharmaceutical wholesalers and to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by various end-users, including hospitals, integrated delivery networks and alternative site facilities. For the year ended December 31, 2014, the products the company sold through its three major wholesalers, AmerisourceBergen Corp., Cardinal Health Inc., and McKesson Corp. accounted for approximately 35%, 25% and 25%, respectively, of its consolidated net revenue. Intellectual Property The company’s trademarks include Sagent Pharmaceuticals, Sagent, Injectables Excellence, Discover Injectables Excellence, Omega and PreventIV Measures. Joint Venture In 2007, the company and Strides Arcolab International Limited, a company based in the United Kingdom and a wholly-owned subsidiary of Strides Arcolab Limited, entered into a joint venture agreement pursuant to which the parties formed Sagent Agila LLC. Key Suppliers and Marketing Partners Two of the company’s business partners, A.C.S. Dobfar S.p.a. and Gland Pharma Limited provide the company with products. Competition The company’s principal competitors include Fresenius Kabi, a division of Fresenius SE; Hospira, Inc.; Pfizer Inc.; Sandoz International GmbH, a division of Novartis AG; Teva Pharmaceutical Industries Ltd.; and West-Ward Pharmaceutical Corp, a subsidiary of Hikma PLC. History The company was founded in 2006 as Sagent Holding Co., a Cayman Islands company. It was incorporated in 2006 in the province of Sichuan of the People’s Republic of China. The company was reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering in 2011.
sagent pharmaceuticals inc
(SGNT:Consolidated Issue Listed on NASDAQ Global Select )
1901 North Roselle Road
Schaumburg, IL 60195
|Amphastar Pharmaceuticals Inc||$11.39 USD||-0.13|
|OraSure Technologies Inc||$4.42 USD||-0.169|
|Pernix Therapeutics Holdings Inc||$3.15 USD||-0.075|
|SciClone Pharmaceuticals Inc||$7.00 USD||-0.065|
|Sucampo Pharmaceuticals Inc||$19.21 USD||-0.04|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.